Search research articles
Contact Us
Filters
Showing results (221-230 of 303) with videos related to
Page
of 31
Sort By:
The Journal of Biological Chemistry
|
November 6, 2009
Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy
Xue Wei Meng, Michael P Heldebrant, Karen S Flatten, et al.
Leukemia Research
|
September 29, 2017
Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia
Jonathan A Webster, Raoul Tibes, Larry Morris, et al.
Leukemia
|
December 18, 2018
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Jorge E Cortes, Florian H Heidel, Andrzej Hellmann, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
March 21, 2006
Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions
Carol Ann Huff, Ephraim J Fuchs, B Douglas Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 6, 2010
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate
B Douglas Smith, Yvette L Kasamon, Jeanne Kowalski, et al.
Leukemia Research
|
September 17, 2025
Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities
J Preston Claiborne, Daniel Li, Hua-Ling Tsai, et al.
Haematologica
|
September 21, 2023
Outcome heterogeneity of <i>TP53</i>-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation
Sergiu Pasca, Saurav D Haldar, Alexander Ambinder, et al.
Leukemia Research
|
September 14, 2016
Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies
Kelly J Norsworthy, Eunpi Cho, Jyoti Arora, et al.
Journal of Translational Medicine
|
July 12, 2017
Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy
Meghali Goswami, Gabrielle Prince, Angelique Biancotto, et al.
Blood Neoplasia
|
September 15, 2025
Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML
Andrew D Zale, Venkata Preetam Sandeep Kaduluri, Jonathan A Webster, et al.
Page
of 31
Search research articles
Search
Showing results (221-230 of 303) with videos related to
Sort By:
Page
of 31
The Journal of Biological Chemistry
|
November 6, 2009
Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy
Xue Wei Meng, Michael P Heldebrant, Karen S Flatten, et al.
Leukemia Research
|
September 29, 2017
Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia
Jonathan A Webster, Raoul Tibes, Larry Morris, et al.
Leukemia
|
December 18, 2018
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Jorge E Cortes, Florian H Heidel, Andrzej Hellmann, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
March 21, 2006
Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions
Carol Ann Huff, Ephraim J Fuchs, B Douglas Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 6, 2010
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate
B Douglas Smith, Yvette L Kasamon, Jeanne Kowalski, et al.
Leukemia Research
|
September 17, 2025
Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities
J Preston Claiborne, Daniel Li, Hua-Ling Tsai, et al.
Haematologica
|
September 21, 2023
Outcome heterogeneity of <i>TP53</i>-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation
Sergiu Pasca, Saurav D Haldar, Alexander Ambinder, et al.
Leukemia Research
|
September 14, 2016
Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies
Kelly J Norsworthy, Eunpi Cho, Jyoti Arora, et al.
Journal of Translational Medicine
|
July 12, 2017
Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy
Meghali Goswami, Gabrielle Prince, Angelique Biancotto, et al.
Blood Neoplasia
|
September 15, 2025
Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML
Andrew D Zale, Venkata Preetam Sandeep Kaduluri, Jonathan A Webster, et al.
Page
of 31